Apart from Eni (E) and Royal Dutch Shell (RDS.A), developments at BP plc (BP), Helmerich & Payne (HP) and Delek US Holdings (DK) during the week remained in focus.
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.
Nu Skin (NUS) gains on its solid customer base and network of sales leaders. The company's three transformational strategies also bode well amid pandemic-led disruptions.
A notable announcement that impressed investors this year is Earthstone Energy's (ESTE) recent deal to acquire Northern Delaware Basin assets for roughly $604 million.